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Abstract: Claudin 4 is a cellular adhesion molecule that is frequently overexpressed in 
ovarian cancer and other epithelial cancers. In this study, we sought to determine whether 
the expression of claudin 4 is associated with outcome in ovarian cancer patients and may 
be involved in tumor progression. We examined claudin 4 expression in ovarian cancer 
tissues and cell lines, as well as by immunohistochemical staining of tissue microarrays 
(TMAs; n = 500), spheroids present in patients’ ascites, and spheroids formed in vitro. 
Claudin 4 was expressed in nearly 70% of the ovarian cancer tissues examined and was 
differentially expressed across ovarian cancer subtypes, with the lowest expression in clear 
cell subtype. No association was found between claudin 4 expression and disease-specific 
survival in any subtype. Claudin 4 expression was also observed in multicellular spheroids 
obtained from patients’ ascites. Using an in vitro spheroid formation assay, we found that 
NIH:OVCAR5 cells treated with shRNA against claudin 4 required a longer time to form 
compact spheroids compared to control NIH:OVCAR5 cells that expressed high levels of 
claudin 4. The inability of the NIH:OVCAR5 cells treated with claudin 4 shRNA to form 
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compact spheroids was verified by FITC-dextran exclusion. These results demonstrate a 
role for claudin 4 and tight junctions in spheroid formation and integrity. 
Keywords: ovarian cancer; claudin 4; biomarker; spheroid; ascites 
 
1. Introduction  
Ovarian cancer is the most lethal gynecological malignancy, resulting in approximately 125,000 
deaths yearly, worldwide [1]. Due to the paucity of specific symptoms and the lack of an effective 
screening method, the majority of ovarian cancers are diagnosed at late stages of malignancy, after the 
tumor  has  spread  beyond  the  ovary  [2].  Although  initial  response  to  treatment  (surgery  and 
chemotherapy)  is  favorable,  most  patients  will  relapse  with  tumors  that  are  chemoresistant  and 
ultimately die of their disease.  
In contrast to other solid tumors, the most common method for ovarian cancer metastasis is direct 
peritoneal  spread.  Tumor  cells  slough  off  the  ovary  into  the  peritoneal  fluid  where  they  are 
disseminated throughout the abdominal cavity, and subsequently attach to the mesothelial cell lining 
and  invade,  forming  metastatic  outgrowths  [3].  Late  stage  cancers  are  frequently  associated  with 
ascites,  and  tumor  cells  can  be  shed  into  the  ascites  fluid  either  as  single  cells  or  multicellular 
aggregates called spheroids. Spheroids suspended in the ascites fluid were previously thought to be 
quiescent. However, we and others have shown that ovarian cancer spheroids are a source of tumor 
invasion and metastasis [4–8]. Spheroids are also chemoresistant [9,10], implicating spheroids as a 
factor in disease persistence or recurrence. 
In an effort to find novel biomarkers for ovarian cancer using gene expression profiling, we and 
others [11–15] have identified claudin 4 as a gene that is highly overexpressed in ovarian cancer, and 
thus may contribute to tumor formation and metastasis. Claudins are a family of cellular adhesion 
molecules  that  are  components  of  tight  junctions,  which  play  important  roles  in  cell  polarity, 
paracellular transport, and the formation of epithelial cell sheets which serve as a barrier in tissues. 
Claudin expression in normal cells is tissue specific, and altered claudin expression has been identified 
in multiple cancer types [16,17]. Consistent with the idea that tumor formation is associated with tight 
junction disruption, downregulation of claudin family members has been reported in some cancers, and 
is associated with a poor prognosis or metastatic disease [18–27]. In contrast, claudin expression may 
also be elevated in different types of cancers and associated with a metastatic phenotype [28–33].  
In this study, we sought to validate the overexpression of claudin 4 that we previously observed in 
ovarian  cancer  tissues  in  our  gene  microarray  experiments  [12]. We  have  evaluated  the  levels  of 
claudin 4 RNA and protein in ovarian cancer tissues and cell lines using RT-PCR, qRT-PCR, Western 
immunoblotting, and immunohistochemistry, in order to assess the potential of claudin 4 as an ovarian 
cancer biomarker. We also sought to determine whether claudin 4 overexpression could be correlated 
with relevant clinical outcomes using tissue microarrays comprised of 500 cases of clinically annotated 
ovarian cancer. Finally, because of its role in intercellular adhesion, and the importance of ovarian 
cancer spheroids in ovarian cancer metastasis and chemoresistance, we examined the expression of 
claudin 4 in ovarian cancer spheroids and its potential role in spheroid formation. Int. J. Mol. Sci. 2011, 12                       
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2. Results and Discussion 
2.1. Claudin 4 RNA Is Overexpressed in Ovarian Cancer 
Our previous analysis of gene expression in human tissues identified claudin 4 as one of 66 genes 
that were upregulated in serous ovarian cancer relative to normal ovaries and over 300 other normal 
and diseased tissues [12]. Our initial validation identified claudin 4 as one of three genes that best 
distinguished between ovarian carcinoma and normal ovary tissues [12]. To further validate our gene 
expression studies, we examined the expression of claudin 4 RNA in ovary tissues and cell lines. 
Consistent with our microarray data, RT-PCR showed 5/5 serous ovarian cancer tumor tissue samples 
tested were positive for claudin 4 compared to only 2/6 normal ovary samples (data not shown). Other 
groups have also identified claudin 4 RNA upregulation in ovarian cancer tissues [11,13–15] as well as 
pancreatic, prostate, and squamous cell carcinomas [29,31,34–36].  
Because surface epithelial cells comprise only a minor fraction of the normal ovary, we examined 
the  expression  of  claudin  4  in  ovarian  cancer  and  immortalized  normal  ovarian  surface  epithelial 
(NOSE) cell lines. We also used ovarian cancer cell lines as a more pure population of tumor cells, 
without contaminating stroma and other cell types. Similar to what others have reported [32,37], we 
found the level of claudin 4 RNA in ovarian cancer cell lines was varied. By qRT-PCR, we found the 
cell lines OVCA433, C-13, OVCAR5, OV2008, CAOV3, and SKOV3 express high levels of claudin 4 
mRNA, while the cell lines OVCA 429, ES-2, MA148, HEY, and A2780-CP (as well as all of the 
NOSE cell lines) were found to express low levels of claudin 4 mRNA (Figure 1A). The variable 
expression  of  claudin  4  in  ovarian  cancer  cell  lines  suggests  that  claudin  4  expression  may  be 
associated with functional  characteristics  of the cell lines, such as proliferation rate or aggressive 
behavior. In other studies, the expression of claudin 4 in ovarian cancer cell lines has been shown to 
increase cell migration and invasion [28]. 
2.2. Claudin 4 Protein Is Overexpressed in Ovarian Cancer Cell Lines and Tissues  
We next examined claudin 4 protein expression by Western immunoblot analysis in both cell lines 
and tissues. Claudin 4 protein was detected in the six ovarian cancer cell lines that expressed high 
levels  of  claudin  4 RNA  (OVCA433,  C-13, OVCAR5, OV2008, CAOV3,  and SKOV3), whereas 
ovarian cancer cell lines with low levels of claudin 4 RNA expression and all of the NOSE cell lines 
were negative for claudin 4 protein by Western blot (Figure 1B). These results, coupled with the  
qRT-PCR data, led us to select the NIH:OVCAR5 and MA148 cell lines for subsequent experiments in 
this study. We observed that all seven primary tumors from women with stage III/IV serous ovarian 
cancer tested were positive for claudin 4 protein expression (Figure 1C). Although some claudin 4 
transcripts were detected in normal ovaries by RT-PCR, by Western blotting, none of the five normal 
ovary tissues tested were positive for expression of claudin 4 protein (Figure 1C). These results are 
supported by other recent studies in which claudin 4 protein expression was demonstrated in lysates 
from ovarian cancer cell lines, but not in cultures of NOSE cells [32,37,38]. One caveat to this is the 
emerging  concept  that  some  ovarian  cancers,  in  particular  serous  subtype  tumors,  arise  from  the 
fimbria of the fallopian tubes [39], which could limit the validity of normal ovaries for comparison of 
gene expression in these and other experiments [11,13–15,32,37,38]. Int. J. Mol. Sci. 2011, 12                       
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Figure 1. Claudin 4 RNA and protein expression in ovarian cancer tissues and cell 
lines. (A) Claudin 4 RNA expression in 13 ovarian cancer cell lines and 7 NOSE cell lines 
as  determined  by  qRT-PCR.  Expression  values  shown  as  fold  change  over  the  lowest 
expressing cell line (1816-575), and are the average of two experiments (see Experimental 
section).  (B)  Claudin  4  protein  expression  was  determined  by  Western  immunoblot 
analysis of ovarian cancer and NOSE cell lines (50 µg protein/lane). -actin serves as a 
loading control. (C) Claudin 4 protein expression was determined by Western immunoblot 
analysis of 7 primary stage III/IV serous ovarian cancer tissues (C1–C7) and 5 normal 
ovaries (N1-N5) (50 µg protein/lane). -actin, loading control. 
 
2.3. Claudin 4 Protein Expression in Ovarian Cancer Tissues 
In previous immunohistochemical (IHC) studies, we observed that claudin 4 staining was localized 
to the cell membrane of frozen sections from 15 serous ovarian cancer primary tumors, and 15 serous 
ovarian cancer tumors metastatic to the omentum; no claudin 4 staining was observed in the surface 
epithelial cells of the 15 normal ovaries that were examined [12]. These earlier studies used fresh, 
snap-frozen  tissues that were  embedded in  OCT, so that the antigens  would not  be destroyed by 
fixatives, increasing the likelihood that the antibodies would recognize the antigens in the tissues. In 
the  current  study,  we  initially  performed  IHC  staining  using  a  test  set  of  58  formalin-fixed  
paraffin-embedded (FFPE) tissue blocks including 21 FFPE cases of normal ovaries with intact surface 
epithelial cells. The FFPE tissue sections were used in order to determine if formalin fixation would 
interfere with the detection of claudin 4, and to optimize the staining methodology for subsequent 
FFPE tissue microarrays. In the test set of FFPE tissues, we observed that staining for claudin 4 in Int. J. Mol. Sci. 2011, 12                       
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ovarian  cancer  cells  was  localized  to  the  cancer  cell  membranes  with  some  cytoplasmic  blush  
(Figure 2A). Overall, the ovarian cancer tumor cells, but not stroma, had a high percentage of claudin 
4 staining in the individual sections. Normal ovarian surface epithelium was either negative or had a 
slight blush of staining present. Claudin 4 staining was observed in 64% of the serous ovarian cancer 
tissues (21/33), 75% of the clear cell ovarian cancer tissues (3/4), and only 19% of the normal ovary 
tissues (4/21). The successful optimization of IHC staining for FFPE tissues and the results showing 
increased levels of claudin 4 expression in serous ovarian cancer tissues compared to normal ovaries, 
not only validated our previous results [12], but led us to examine claudin 4 expression in a much 
larger cohort of patients.  
Figure 2. Claudin 4 immunohistochemical staining of FFPE tissues. (A) Representative 
claudin 4 staining of whole mount sections of serous ovarian cancer and normal ovary. 
Top, 200×  magnification; bottom, enlargement to show detail. (B) Examples of claudin 4 
staining and scoring for TMA samples: 0, no cancer cells staining; +1, <10% of cancer 
cells staining; +2, 10–50% of cancer cells staining; +3, >50% of cancer cells staining. In 
some cases, positive scores (1, 2, and 3) were binarized for analysis. 
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2.4. Claudin 4 Protein Is Differentially Expressed between Subtypes of Ovarian Cancer 
To  determine  whether  other  subtypes  of  ovarian  cancer  would  also  show  increased  levels  of 
expression and if claudin 4 expression in ovarian cancer was associated with outcome or other clinical 
parameters, we performed immunohistochemical staining of claudin 4 on tissue microarrays (TMA). 
The  TMAs  encompassed  500  cases  of  epithelial  ovarian  cancer  of  different  subtypes  (serous, 
mucinous, endometrioid and clear cell; Table 1; Figure 2B); each tissue was associated with patient 
clinical data, including up to 20 years of follow-up [40]. Overall, claudin 4 expression was observed in 
69.9% of ovarian cancer patients, with differential expression observed between the different ovarian 
cancer subtypes (p = 0.0026; Figure 3A), due to a lower percentage of cells stained in clear cell 
tumors.  The  highest  percentage  of  expression  was  observed  in  the  endometrioid  and  mucinous 
subtypes  (both  77.4%  positive),  compared  to  serous  (72.17%  positive),  and  clear  cell  (57.58% 
positive) subtypes. These results extend the previous analysis of claudin 4 expression in ovarian cancer 
subtypes [32,37,38,41], which are generally in agreement with our data. In these prior studies, claudin 
4 expression was elevated in the majority of cases of epithelial ovarian cancer, with approximately 
70% of serous ovarian cancers staining positively for claudin 4 [32,37,38,41]. However, in contrast to 
our results showing that the endometrioid and mucinous subtypes of ovarian cancer had the highest 
levels of claudin 4 expression, Litkouhi et al. found the highest percentage of claudin 4 staining in 
endometrioid and clear cell subtypes, although with a much smaller sample size [37]. 
Table 1. Subtype, stage, Silverberg grade, and Claudin 4 score of ovarian cancer tissue 
microarrays. 
Subtype  Median Age 
(range) 
Stage  N  Claudin 4 
Positive (%) 
Silverberg 
Grade 
N  Claudin 4 
Positive (%) 
Claudin 4 Positive 
Overall (%) 
Serous  
(n = 212) 
59.6 
(33.5–86.0) 
I  50  33 (66.0%)  1  12  7 (58.3 %)  153 (72.2 %) 
II  93  69 (74.2%)  2  56  37 (66.1%) 
III  69  51 (73.9%)  3  144  109 (75.7%) 
Endometrioid  
(n = 125) 
54.1  
(29.4–88.1) 
I  69  54 (78.3%)  1  82  66 (81.5%)  96 (77.4 %) 
II  50  37 (75.5%)  2  35  27 (77.1%) 
III  6  5 (83.3%)  3  8  3 (37.5%) 
Clear Cell 
(n = 132) 
55.0  
(28.1–89.0) 
I  68  45 (66.3%)  1  0*  N/A  76 (57.6 %) 
II  56  26 (46.4%)  2  0*  N/A 
III  8  5 (62.5%)  3  132  76 (57.6 %) 
Mucinous 
(n = 31) 
56.4 
(25.4–76.7) 
I  18  15 (83.3%)  1  11  8 (72.7%)  24 
(77.4%)  II  12  8 (66.7%)  2  18  14 (77.8%) 
III  1  1 (100%)  3  2  2 (100.0%) 
Total 
(n = 500) 
56.6 
(25.4–89.0) 
I  205  147 (71.7%)  1  105  81 (77.1%)  349 
(69.9%)  II  211  140 (66.4%)  2  109  78 (71.6%) 
III  84  62 (73.8%)  3  286  190 (66.4%) 
* All clear cell carcinomas are considered high grade. Int. J. Mol. Sci. 2011, 12                       
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Figure  3.  Claudin  4  expression  in  ovarian  cancer  subtypes  in  tissue  microarrays.  
(A) Claudin 4 is differentially expressed in ovarian cancer subtypes (p = 0.0026). Percent 
of TMA cases positive for claudin 4 staining in ovarian cancer subtypes. Staining score: 
black, score +1 (<10% of cancer cells staining); white, score +2 (10–50% of cancer cells 
staining); gray, score +3 (>50% of cancer cells staining). (B) Claudin 4 expression by 
Silverberg Grade. Percent of TMA cases positive for claudin 4 by Silverberg Grade (grade 
1 is black; grade 2 is diagonal stripe; grade 3 is gray). Positive scores (1, 2, and 3) were 
binarized. Claudin 4 expression is significantly lower in high grade endometrioid ovarian 
cancer (p = 0.0178). (C) Percent of TMA cases positive for claudin 4 by stage (stage I is 
black; stage II is diagonal stripe; stage  III is  gray). Positive scores (1, 2, and 3) were 
binarized. Claudin 4 expression was not significantly different between the stages. 
 
 
Claudin 4 expression was also analyzed in each subtype by Silverberg grade and stage (Figures 3B 
and  3C).  In  the endometrioid  subtype, claudin  4  was  differentially expressed  by Silverberg  grade  
(p = 0.0178), and was inversely associated with grade; 81.48% of Grade 1 tumors were claudin 4 
positive, 77.14% of Grade 2 tumors were claudin 4 positive, and 37.5% of Grade 3 tumors were 
claudin 4 positive. In contrast, previous studies that examined primarily serous tumors suggested that 
claudin 4 expression was increased in undifferentiated tumors [37,38]; however, those studies included 
only  a  small  number  of  non-serous  subtype  tumors.  No  other  associations  between  claudin  4 
expression and stage or Silverberg grade were observed.  Int. J. Mol. Sci. 2011, 12                       
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Figure 4. (A) Kaplan-Meyer survival curve of TMA data for 500 ovarian cancer patients 
showing disease-specific survival measured in days. (B) Kaplan-Meyer survival curve of 
TMA data for 500 ovarian cancer patients showing relapse-free survival measured in days. 
Red, staining score 0; green, staining score +1; blue, staining score +2; orange, staining 
score +3.  
 
Figure 5. Disease-specific survival by ovarian cancer subtype. Kaplan-Meyer survival 
curve of TMA data for ovarian cancer patients shown by subtype. Disease-specific survival 
measured in days. Positive scores were binarized and are shown in gray. Black, claudin 4 
negative. 
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As  shown  by  Kaplan-Meier  curves  (Figure  4),  there  was  no  association  between  claudin  4 
expression and disease-specific survival or relapse-free survival in ovarian cancer overall. When the 
survival data was examined by histological subtype (Figure 5), there was no significant association 
between claudin 4 expression and survival in any of the ovarian cancer subtypes. In a smaller cohort of 
42 high grade serous tumors, Litkouhi et al. also found no association between claudin 4 expression 
and survival [37]. In contrast, Lanigan et al. recently reported that overexpression of claudin 4 was 
associated  with  an  adverse  outcome  in  breast  cancer  [30].  Similarly,  claudin  4  overexpression  is 
associated with poor outcome in clear cell renal cell carcinoma [42]. Although the results from the 
TMA studies did not provide an association between claudin 4 protein expression and survival, an 
important  finding  was  made.  Namely,  the  data  shows  that  claudin  4  protein  is  expressed  by  the 
majority of ovarian cancer tissues, but not by normal surface epithelial cells of the ovary, and thus may 
serve as a target for therapy. The implications for the role of claudin 4 in other functional aspects of 
ovarian cancer dissemination were therefore pursued. 
2.5. Claudin 4 Plays a Role in Spheroid Formation/Integrity 
Our finding that claudin 4 is localized primarily to the membrane in immunohisotchemically stained 
slides corresponds to previous reports by ourselves and others [13,15,37]. However, other studies have 
shown claudin 4 staining of both the cytoplasm and membrane in some serous ovarian cancer tumors, 
suggesting  that  in  addition  to  its  role  in  tight  junction  formation,  claudin  4  may  have  additional 
functions  regulating  proliferation  or  differentiation  [32,38].  In  an  effort  to  explore  the  potential 
functional role of claudin 4 in ovarian cancer dissemination and determine whether functional tight 
junctions  are  formed,  we  examined  claudin  4  protein  expression  and  localization  by 
immunocytochemistry in cells from the ascites of ovarian cancer patients. Late stage ovarian cancers 
are frequently associated with the accumulation of peritoneal ascites fluid, which may contain ovarian 
cancer cells present either singly or as multicellular spheroids. Eight of 10 ascites samples showed 
positive claudin 4 membrane staining, either in single cells or multicellular aggregates (spheroids) or 
both, with strong staining visible at the points of cell-cell contact (Figure 6, arrows). Our findings are 
consistent with those of Kleinberg et al., who observed claudin 4 staining in over 90% of 218 ovarian 
cancer effusions examined [43]. 
To determine whether the expression of claudin 4 may affect the formation of the spheroids which 
are frequently found in the ascites of ovarian cancer patients, we engineered two ovarian cancer cell 
lines to express different levels of claudin 4. The Western blot in Figure 7A shows no endogenous 
expression of claudin 4 in the MA148 cell line, while the NIH:OVCAR5 cell line expresses high levels 
of endogenous claudin 4. A claudin 4 transgene was then ectopically expressed in MA148 cells, and 
claudin 4 protein was shown to be expressed at high levels (Figure 7A). Conversely, NIH:OVCAR5 
cells were transfected with an shRNA directed against claudin 4, resulting in a decrease in claudin 4 
expression levels (Figure 7A).  
Immunocytochemistry of spheroids formed in vitro from cultured cells expressing different levels 
of claudin 4 show claudin 4 localized to the membrane in cultured spheroids, similar to spheroids from 
patient ascites (Figure 7B). Although the NIH:OVCAR5 cells expressing an shRNA against claudin 4 
have substantially reduced levels of claudin 4 protein, they were still able to form spheroids. Similarly, Int. J. Mol. Sci. 2011, 12                       
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the ovarian cancer cell line MA148 had undetectable levels of claudin 4 expression, yet these cells 
formed  compact  multicellular  spheroids  in  vitro;  demonstrating  that  claudin  4  expression  is  not 
essential for spheroid formation. Previous analysis of breast and ovarian cancer cell lines suggests that 
a  diverse  array  of  adhesion  molecules,  including  cadherins  and  beta  1  integrin,  are  involved  in 
spheroid formation in vitro, depending on the cell line [8,44]. 
Figure 6. Claudin 4 expression in patient spheroids. Immunocytochemical staining of 
spheroids isolated from the ascites of two representative stage III/IV serous ovarian cancer 
patients. Spheroids were stained with either an antibody against claudin 4 or normal mouse 
IgG, followed by a FITC-conjugated secondary antibody (green). Nuclei were stained with 
DAPI (blue). Arrows indicate claudin 4 staining at sites of cell-cell contact. Bar = 20 µm. 
 
2.6. Claudin 4 Increases the Rate of Ovarian Cancer Spheroid Formation 
Although claudin 4 is not absolutely required for spheroid formation, we examined in vitro spheroid 
formation over time in ovarian cancer cells expressing different levels of claudin 4. For both ovarian 
cancer cell lines tested (NIH:OVCAR5 and MA148), tight, round multicellular aggregates or spheroids 
formed from single cells after approximately 24 hr. The size of the spheroids formed in vitro was at 
least partially dependent upon the number of cells plated (data not shown). As shown in Figure 8, the 
three-dimensional structures formed by NIH:OVCAR5 cells differed according to their expression of 
claudin 4 shortly after seeding. The parental NIH:OVCAR5 ovarian cancer cell line expressed high 
levels of claudin 4 and was able to form compact spheroids in vitro after 24 hr in culture, while the 
spheroids  formed  from  NIH:OVCAR5  cells  treated  with  shRNA  targeting  claudin  4  remained  as Int. J. Mol. Sci. 2011, 12                       
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loosely associated aggregates. The time required to form “true spheroids” (defined as tight round, 
regular, large, nonpermeable structures) increased in the absence of claudin 4 from about 24 hr for 
NIH:OVCAR5 cells to over 60 hr for NIH:OVCAR5 cells treated with shRNA targeting claudin 4. 
Although the differences in spheroid structure between NIH:OVCAR5 cells and NIH:OVCAR5 cells 
treated with shRNA diminished over time, the size of the spheroids after 72 hr suggests that increased 
levels of claudin 4 expression contribute to compact spheroid formation. In addition to the parental 
NIH:OVCAR5 cells, an empty vector control could also have served as a negative control; however, 
the Western blot in Figure 7A shows similar levels of beta actin in the parental and shRNA cells, 
suggesting that the shRNA does not have any generalized “off-target” effects in NIH:OVCAR5 cells. 
Figure 7. (A) Western blot showing claudin 4 expression levels in ovarian cancer cell lines 
engineered  to  express  different  levels  of  claudin  4  (10  µg  protein/lane):  MA148  cells 
transfected with claudin 4; MA148 cells transfected with an empty vector; NIH:OVCAR5 
cells;  and  NIH:OVCAR5  cells  treated  with  shRNA  targeted  to  claudin  4.  (B)  In  vitro 
cultured  spheroids  from  cell  lines  engineered  to  express  different  levels  of  claudin  4. 
Spheroids were cultured for 48 hours, then stained with an antibody against claudin 4 
followed  by  a  FITC-conjugated  secondary  antibody  (green).  Nuclei  were  stained  with 
DAPI (blue). Top left, MA148 cells transfected with an empty vector; bottom left, MA148 
cells  transfected  with  claudin  4;  top  right,  NIH:OVCAR5  cells;  and  bottom  right, 
NIH:OVCAR5 cells treated with shRNA targeted to claudin 4. Bar = 50 µm. 
 
Our  analysis  of  the  time  to  spheroid  formation  shows  that  claudin  4  expression  contributes  to 
compact spheroid structure. Sodek et al. previously showed that the formation of compact spheroids 
by ovarian cancer cells was associated with contractile behavior and an invasive phenotype [8]. Cancer 
cells grown as spheroids are also known to be chemoresistant, which is due, in part, to their structure 
[9].  Perhaps  claudin  4  and  tight  junctions  contribute  to  this  by  functioning  as  a  barrier  to 
chemotherapy.  Alternatively,  cell-cell  adhesion  could  activate  prosurvival  signaling  in  spheroids Int. J. Mol. Sci. 2011, 12                       
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[10,45–47].  Interestingly,  claudin  4  was  identified  in  a  proteomic  analysis  of  chemoresistance  in 
ovarian cancer as one of 58 proteins that were overexpressed in cisplatin resistant cells [48]. 
Figure 8. Time course of spheroid formation in NIH:OVCAR5 cells. Spheroids were 
formed in vitro using the liquid overlay method. Cells were grown in 96-well plates, with 
2400  cells  plated  per  well.  Spheroid  formation  was  observed  at  intervals  over  72  hr. 
Experiments were repeated at least twice. Bar = 500 µm. 
 
The time required for MA148 cells to form spheroids was not dependent upon the presence of 
transfected claudin 4 (data not shown). The ability of MA148 cells to form spheroids in the absence of 
claudin 4 suggests that a redundant system of cell-cell adhesion may be used for spheroid formation. Int. J. Mol. Sci. 2011, 12                       
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Other claudins, especially claudin 3, are also overexpressed in ovarian cancer and could be part of this 
redundancy [11,13–15,32,38,44,49]. 
2.7. Claudin 4 Decreases Paracellular Permeability 
We also examined the paracellular permeability of spheroids expressing different levels of claudin 4 
by  testing the  ability of  spheroids  formed in vitro to exclude FITC-dextran. At early  time  points  
(1–3 days), more compact spheroids capable of dye exclusion were formed in NIH:OVCAR5 cells 
compared to NIH:OVCAR5 cells treated with shRNA targeting claudin 4 (Figure 9); suggesting that 
claudin 4 levels are related to paracellular permeability and tight junction barrier function in spheroids. 
No difference in dye exclusion was observed at 8 days (data not shown). Differences in paracellular 
permeability between the empty vector and the claudin 4 transfected MA148 cells were more subtle. 
Slight differences in dye infiltration were observed, but overall the 3D structure and tightness of the 
spheroids did not appear to be affected (data not shown).  
Figure 9. Paracellular permeability of cultured spheroids expressing different levels 
of claudin 4. (A) Photograph taken on fluorescent microscope en face of NIH:OVCAR5 
spheroids incubated in FITC-dextran. (D) Photograph taken on fluorescent microscope en 
face  of  NIH:OVCAR5  spheroids  treated  with  shRNA  targeting  claudin  4  incubated  in 
FITC-dextran. Spheroids in (A) that express high levels of claudin 4 are tighter than those 
in (D) that express low levels of claudin 4. The fluorescence level of the perpendicular (Z) 
planes indicated by the horizontal yellow lines in (A) and (D) are shown in panels (B) and 
(E); providing a cross-sectional view of the tight aggregates (A, B) vs. the loose aggregates 
(D, E). Bar = 20 µm. Panels (C) and (F) show fluorescence profiles of spheroids in panels 
(B) and (E) as described in the Experimental section.  
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Paracellular resistance in ovarian cancer cell monolayers has been shown to be directly related to 
levels of claudin 4 expression [37]. Further studies have shown that phosphorylation of claudin 4 
decreases the assembly of claudin 4 in tight junctions, thereby enhancing paracellular permeability 
[50,51]. In colon cancer cells, overexpression of claudin 4 decreased paracellular permeability and 
increased invasiveness [33]. Together with the observation that compact ovarian cancer spheroids are 
more invasive than diffuse spheroids [8], our results suggest that increased claudin 4 expression could 
be associated with invasiveness in ovarian cancer as well. Again, our TMA findings that claudin 4 
protein was expressed by the majority of ovarian cancer tissues suggest that claudin 4 may serve as a 
target for therapy.In the past, spheroids have been shown to play an important role in ovarian cancer 
dissemination and invasion [5,6,8,52,53] and may also contribute to chemoresistance [9,54]. In this 
work, we showed that cells expressing high levels of claudin 4 were able to form compact spheroids 
more rapidly than cells with lower levels of claudin 4 expression, and paracellular permeability was 
increased in spheroids expressing reduced levels of claudin 4. These results suggest that claudin 4 may 
mediate  chemoresistance  in  spheroids  by  increasing  tight  junction  barrier  function,  and  implicate 
claudin 4 as a target for therapy. The ability of the C-terminal fragment of the Clostridium perfringens 
enterotoxin  (CPE),  a  polypeptide  that  causes  food  poisoning  and  binds  to  claudin  4  as  a  cellular 
receptor [55,56], to disrupt tight junction formation and increase paracellular permeability has been 
shown in embryogenesis [57] and ovarian cancer cell lines [37], and could potentially be used to 
increase the sensitivity of ovarian cancer cells to standard chemotherapy [58]. 
3. Experimental Section  
3.1. Reagents 
Cell culture media and supplements were purchased from Invitrogen Corporation (Carlsbad, CA) 
unless  otherwise  stated.  Chemicals  were  purchased  from  Sigma-Aldrich  (St.  Louis,  MO)  unless 
otherwise stated.  
Antibodies used were mouse anti-human claudin 4 (clone 3E2C1; Invitrogen), mouse anti-human  
-actin (clone AC-74; Sigma-Aldrich), and normal mouse IgG (clone 3-5D1-C9; AbCam). Secondary 
antibodies used were FITC-conjugated goat anti-mouse IgG + IgM (Roche Diagnostics, Indianapolis, 
IN),  stabilized  horseradish  peroxidase-conjugated  goat  anti-mouse  IgG  (Thermo  Fisher  Scientific, 
Rockford, IL), and biotinylated horse anti-mouse IgG (Vector Laboratories, Burlingame, CA). 
3.2. Cell Lines 
Ovarian  cancer  cell  lines  SKOV3,  ES-2,  NIH:OVCAR3,  HEY,  C-13,  OV2008,  OVCA429, 
OVCA433, A2780-S, and A2780-CP (provided by Dr. Barbara Vanderhyden, University of Ottawa, 
Canada), NIH:OVCAR5 (provided by Dr. Judah Folkman, Harvard Medical School, Boston, MA), 
CAOV3 (provided by Dr. Robert Bast Jr., University of Texas, Houston, TX), and MA148 (provided 
by  Dr.  Sundaram  Ramakrishnan,  University  of  Minnesota,  Minneapolis,  MN)  were  maintained  as 
previously described [6,59–61]. SKOV3, ES-2, and OVCA429 cell lines were derived from clear cell 
carcinomas; OV2008 and C-13 cell lines were derived from endometrioid tumors; NIH:OVCAR3, Int. J. Mol. Sci. 2011, 12                       
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NIH:OVCAR5, OVCA433, CAOV3, HEY, MA148, A2780-S, and A2780-CP cell lines were derived 
from serous adenocarcinomas [59,60]. 
Immortalized normal ovarian surface epithelial (NOSE) cell lines 1816-575, 1816-686, IMCC3, 
IMCC5, and HIO117 (provided by Dr. Patricia Kruk, University of South Florida, Tampa, FL), and 
IOSE-29 and IOSE-80 (provided by Dr. Nelly Auersperg, University of British Columbia, Vancouver, 
BC,  Canada)  were  also  maintained  as  described  [62,63].  Cells  were  maintained  in  a  humidified 
chamber at 37 °C  with 5% CO2 and were routinely subcultured with trypsin/EDTA. 
3.3. shRNA Knockdown of Claudin 4 
NIH:OVCAR5  cells  were  stably  transfected  with  shRNA  clone  TRCN0000116631  (Open 
Biosystems, Huntsville, AL) plasmid DNA using Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s instructions.  
3.4. Transfection of MA148 Cells with Claudin 4 
The claudin 4 coding sequence was amplified from CAOV3 total RNA using the Access one step 
RT-PCR  kit  (Promega,  Madison,  WI)  with  primers;  Forward,  AGATCTATGGCCTCCATGGGG; 
Reverse, TCTAGATTACACGTAGTTGCTGGCAGC, and cloned into the TA cloning vector pCR2.1 
(Invitrogen) according to the manufacturer’s instructions. The claudin 4 coding fragment was excised 
from  pCR2.1  by  digestion  with BglII  and XbaI and  ligated into the pcDNA3.1 expression vector 
(Invitrogen), and the sequence and orientation were verified by sequencing with vector primers. The 
pcDNA3.1-claudin 4 plasmid was transfected into MA148 cells using Lipofectamine 2000 (Invitrogen) 
according to the manufacturer’s instructions. Stable clones were selected with neomycin. 
3.5. Tissue Samples 
Snap-frozen  tissue  samples  and  formalin-fixed,  paraffin-embedded  (FFPE)  tissue  blocks  were 
obtained from the University of Minnesota Tissue Procurement Facility (TPF) after IRB approval. 
Snap-frozen tissues were used for isolation of RNA and protein; FFPE tissues blocks were used to 
optimize immunohistochemical staining. The seven snap-frozen ovarian cancer tissues used for RNA 
and protein analysis were derived from the primary ovarian tumors of women with stage III/IV ovarian 
cancer of the serous subtype. The five snap-frozen normal ovarian tissues were obtained from patients 
with benign leiomyomas, endometriosis, benign peritubal cysts, or other non-ovarian diseases. For 
immunohistochemistry, 33 serous tumors, 4 clear cell tumors, and 21 normal ovaries were examined. 
All tissue samples underwent strict quality control measures prior to use in these studies. Namely, 
tumors were diagnosed  by  a pathologist  at the  time of  surgery using  OCT embedded tissue.  The 
following day, the FFPE H&E slides were reviewed by a pathologist to confirm the accuracy of the 
diagnosis. A third pathologist reviewed the quality control H&E slides of all TPF cases to confirm the 
diagnosis  of  the  samples  prior  to  distribution  to  researchers.  Additionally,  a  pathologist  (S.E.P.) 
reviewed the slides while scoring the IHC staining. Int. J. Mol. Sci. 2011, 12                       
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3.6. Isolation of Spheroids from the Ascites of Ovarian Cancer Patients 
Ascites fluid was obtained from the University of Minnesota Tissue Procurement Facility after IRB 
approval. Spheroids were isolated from ovarian cancer patient ascites as previously described [5]. 
Briefly,  ascites  was  centrifuged  at  500–700  ×  g  for  10  min  and  erythrocytes  were  lysed  by 
resuspending  cells  in  lysis  buffer  (10  mM  potassium  bicarbonate,  155  mM  ammonium  chloride,  
0.1 mM EDTA, pH 7.5) for 5 min. Remaining cells were collected by centrifugation, washed with PBS 
and  viably  frozen  (10%  dimethyl  sulfoxide  in  fetal  bovine  serum)  and  stored  in  liquid  nitrogen  
until use.  
3.7. RNA Extraction and Reverse Transcriptase Polymerase Chain Reaction 
Total RNA was extracted from cell lines and ovarian tissue samples using the RNeasy Mini kit 
(Qiagen,  Valencia,  CA)  according  to  the  manufacturer’s  instructions.  A  372  bp  sequence 
corresponding to claudin 4 was amplified from 200 ng of total RNA using the following primers: 
Forward,  5’  TGATATCACCTCTGGGACTGT’;  Reverse,  5’  CAGAAACCACAAAGAAGGAAG. 
One-step  RT-PCR  was  performed  with  the  RT-PCR  Access  kit  (Promega,  Madison,  WI),  with 
conditions as follows: 45 min at 45 C; 1 cycle of 94 C, 2 min; 56 °C , 1 min; 72 C, 1 min; 35 cycles of: 
94 C, 30 sec; 56 C, 1 min; 72 C, 1 min; and a final extension at 72 °C  for 7 min. Expression of -actin 
in the samples confirmed that RNA was not degraded and that similar amounts of RNA were loaded  
[-actin primers (Forward, 5’GGCCACGGCTGCTTC; Reverse, 5’GTTGGCGTACAGGTCTTTGC)]. 
These experiments were performed at least two times. 
3.8. Quantitative Reverse Transcriptase Polymerase Chain Reaction 
Real  time  quantification  of  claudin  4  was  performed  using  the  SYBR-green  assay  (Bio-Rad 
Laboratories, Hercules, CA) and the iQ5 Real-Time PCR thermocycler (Bio-Rad). Two micrograms of 
total RNA was used for cDNA synthesis using an oligo dT primer and Superscript III first-strand 
synthesis kit (Invitrogen) according to the manufacturer’s specifications. Two microliters of cDNA 
was amplified in a 25 μL reaction containing 1 µL each of claudin 4 forward and reverse primers 
(Forward, CTTCATCGGCAGCAACATT; Reverse, AGCAGCGAGTCGTACACCTT), and 13 µL of 
iQ  SYBR  green  supermix  (Bio-Rad).  Following  an  initial  denaturation  step  of  95  ° C  for  3  min,  
40 cycles of PCR were performed under the following conditions: 95 °C , 10 sec (denaturation) and  
52 °C , 30 sec (annealing/extension). All real-time PCR reactions were run in duplicate and melt curve 
analysis was performed to determine amplification of a single product. Data was normalized to the 
amount of β-actin present in the sample, determined in a separate reaction [primers β-actin forward: 
AGAGCTACGAGCTGCCTGAC; β-actin reverse: GGATGTCCACGTCACACTTC; and annealing 
temperature 54 °C ]. Transcript levels were quantitated using cRNA standard curves for claudin-4 and 
β-actin [64] and the relative amount of each sample was determined as a fold-change increase over the 
lowest expressing cell line (1816-575). Expression values reported in Figure 1A are the average of two 
experiments, except samples IMCC3, IMCC5, HIO117 and IOSE-29 which were run in duplicate in a 
single experiment.  Int. J. Mol. Sci. 2011, 12                       
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3.9. Western Immunoblotting 
Protein  was  extracted  from  snap-frozen  tissues  in  T-PER  (Tissue  Protein  Extraction  Reagent; 
Thermo  Fisher  Scientific)  containing a protease inhibitor cocktail (Roche Applied Science,  Basel, 
Switzerland). Total protein extracts were also derived from confluent monolayers of cells in 50 mM 
Tris, 150 mM sodium chloride, 1 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 
protease inhibitor cocktail (Roche Applied Science), and 1 mM PMSF then stored at −80 °C . Protein 
concentration  was  determined  using  the  BCA  Protein  Assay  (Thermo  Fisher  Scientific).  Fifty 
micrograms  of  protein  were  separated  on  a  10%  SDS  Tris-HCl  polyacrylamide  gel  or  a  4–20%  
Tris-HCl Criterion precast gel (BioRad), then blotted onto a polyvinylidene difluoride membrane (GE 
Healthcare Limited; Piscataway, NJ). Membranes were blocked with 5% powdered milk (Roundy’s 
Inc.; Milwaukee, WI) in PBS as previously described [65,66], and then incubated in 0.167 μg/mL 
mouse anti-human claudin 4 (clone 3E2C1) overnight, followed by a 2-hr incubation in horseradish 
peroxidase  conjugated  goat  anti-mouse  antibody  diluted  1/5000.  Protein  was  visualized  using  the 
Super  Signal West Femto  kit (Thermo Fisher  Scientific) according to manufacturer’s  instructions. 
Membranes  were  exposed  to  autoradiography  film  (Midwest  Scientific;  Valley  Park,  MO)  and 
developed. Blots were reprobed with an antibody against -actin as a loading control.  
3.10. Immunohistochemical Staining of Tissues 
FFPE tissue sections were deparaffinized and rehydrated through a series of xylene and ethanol 
washes as previously described [66]. Antigen retrieval was performed in a citrate buffer (Biocare, 
Concord, CA) and endogenous peroxidase activity was blocked with hydrogen peroxide. Slides were 
incubated with mouse anti-human claudin 4 monoclonal antibody (clone 3E2C1; Invitrogen) or normal 
mouse IgG1 (clone 3-5D1-C9; AbCam) at 0.25 g/mL overnight. Slides were washed and incubated 
with  biotinylated  horse  anti-mouse  IgG  (Vector  Laboratories,  Burlingame,  CA),  followed  with  an 
avidin:biotin  complex  (Vector  Laboratories).  Staining  was  visualized  with  3,3’-diaminobenzidine 
(Biocare). Slides were examined by a pathologist (S.E.P.) in a blinded manner and assigned a score of 
0 (no staining); 1 (<10% of neoplastic cells staining); 2 (10–50% of neoplastic cells staining); or 3 
(>50% of neoplastic cells staining). FFPE blocks of human intestine were used as a positive control for 
claudin 4 antibody staining.  
3.11. Tissue Microarrays  
TMA  slides  containing  0.6  mm  duplicate  core  samples  for  500  ovarian  cancer  patients  were 
provided  by  the  Cheryl  Brown  Ovarian  Cancer  Outcomes  Unit  (University  of  British  Columbia; 
Vancouver, BC, Canada). Patients included in the TMA were chosen based on having been optimally 
cytoreduced at initial surgery with no macroscopic residual disease remaining. Due to these criteria, a 
significant proportion of early stage cases were present on the TMA relative to the general population 
of patients with ovarian cancer. None of the patients received neoadjuvant therapy and all received 
platinum-based chemotherapy following surgery. The 500 cases included on the TMA were collected 
up to 18 years prior to this analysis. Hematoxylin and eosin stained slides for all cases were reviewed 
by a gynecologic pathologist (C.B.G.) to confirm diagnosis, stage, tumor cell type, and grade prior to Int. J. Mol. Sci. 2011, 12                       
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TMA inclusion to ensure that the current diagnostic criteria for subclassification of ovarian cancer 
based  on  cell  type  were  uniformly  applied  [67,68].  Samples  displaying  multiple  cell  types  
(mixed tumors) were excluded from the study. Details regarding the cohort used for these TMAs are 
provided in Table 1 and in Gilks et al. [40]. Patients were followed for a median of 4.6 (0.1–18) years 
after the initial surgery. Three-tiered grading of ovarian cancer tissues was done using the Silverberg 
grading system at the time of review of the complete slide sets for all cases on the ovarian TMAs [69]. 
Tissue microarray slides were treated and stained identically to the individual tissue sections, and 
scored in a blinded manner as described above. In cases where the duplicate core samples received 
different scores, results were averaged for analysis. For some analyses, scores of 1, 2, and 3 were 
grouped and considered positive (“binarized data”). 
3.12. TMA Statistical Analysis 
Differential expression for claudin 4 across the histopathological subtypes was assessed with the 
Pearson  Chi-Square  statistic.  Univariable  relapse-free  survival  for  the  entire  cohort  and  each 
histopathologic  subtype  was  examined  with  Kaplan-Meier  survival  curves.  Results  significant  in 
univariable analysis were subjected to multivariable relapse-free survival using the Cox Proportional 
Hazards test. The level of significance for all comparisons was p < 0.05. All statistical calculations 
were computed with JMP v. 6.0.3 (SAS Institute Inc., Carey, NC). 
3.13. Spheroid Formation in Vitro 
Spheroids were cultured using the liquid overlay method, as previously described [52]. Briefly,  
96-well  tissue  culture  plates  were coated with 100 µL of 0.5% w/v SeaKem  LE agarose (Lonza, 
Walkersville, MD) in serum-free culture media, to prohibit cell adhesion to the substratum. Plates were 
allowed to cool for at least 30 min at room temperature. Cells grown in monolayer cultures were 
released with 0.5% trypsin, 2 mM ethylenediaminetetraacetic acid (Invitrogen) and resuspended in 
complete  cell  culture  media.  The  cell  suspension  was  run  through  a  70  µm   cell  strainer  (BD 
Biosciences, Bedford, MA) to remove residual clumps. Cells were counted with a hemocytometer, 
then diluted to 2000 to 170,000 cells/mL. Cell suspensions were layered on top of the agarose-coated 
plates at a volume of 100 µL/well and then incubated at 37 °C . 
3.14. Immunocytochemical Staining of Spheroids 
Spheroids either isolated from the ascites of ovarian cancer patients or formed in vitro from ovarian 
cancer cell lines were embedded in thrombin clots and 20 µm  OCT-frozen sections were stained as 
previously described [52]. Alternatively, spheroids were fixed and stained in a 96-well plate prior to 
mounting onto slides. Briefly, spheroids were washed three times with Dulbecco’s phosphate buffered 
saline (DPBS) containing calcium and magnesium, and centrifuged at ~200 ×  g for 5 min. Cells were 
fixed in 200 µL of ice cold 100% methanol overnight at −20 °C , then rehydrated with 3 washes of 
DPBS containing calcium and magnesium. Cells were blocked with 1% normal goat serum, 0.3% 
Tween-20 in DPBS containing calcium and magnesium for 1 hr, then incubated in 100 µL of primary 
antibody at 2.5 µg/mL in blocking buffer overnight at 4 ° C with gentle agitation. Cells were washed Int. J. Mol. Sci. 2011, 12                       
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three  times  in  blocking  buffer  and  incubated  in  a  1:100  dilution  of  secondary  antibody  
(FITC-conjugated goat anti-mouse IgG + IgM; Roche Diagnostics) overnight at 4 ° C in the dark. Cells 
were washed three times in blocking buffer and incubated in 100 µL of a 2.86 ×  10
−7 M DAPI solution 
for 5 min, then washed three times in DPBS containing calcium, magnesium, and 0.3% Tween-20 with 
a  final  wash  in  SlowFade  equilibration  buffer  (Invitrogen,  Eugene,  OR).  Cells  were  mounted  in  
1×  SlowFade reagent in PBS containing 50% glycerol. 
3.15. FITC-Dextran Paracellular Permeability Imaging 
Spheroids were formed in 6-well plates by coating plates with 2 mL agarose as described above. 
Cells were plated in 2 mL complete media at concentrations from 10,000 to 500,000 cells per well and 
spheroids  were  formed  for  48  to  96  hr  at  37  °C .  Thirty  minutes  prior  to  visualization,  a  4  kDa 
conjugate FITC-dextran (Sigma-Aldrich) was added to a final concentration of 0.05–0.1% [33,51]. 
Spheroids were imaged in situ on an Olympus FluoView FV1000 upright confocal microscope with a 
20X water immersion objective and 488 nm laser. Fluorescence intensity profiles were generated with 
Image J 1.37v software. 
4. Conclusions  
In this study, we validated our previous gene microarray data, showing that claudin 4 RNA and 
protein is overexpressed in ovarian cancer tissues and cell lines compared to tissues and cell lines from 
normal ovaries. We also demonstrated that claudin 4 is differentially expressed across histological 
subtypes  of  ovarian  cancer;  however,  no  difference  in  survival  was  observed  between  claudin  4 
positive vs. negative tumors. Claudin 4 was also expressed in ovarian cancer spheroids isolated from 
the ascites of patients. The parental NIH:OVCAR5 ovarian cancer cell line expressed high levels of 
claudin 4 and was able to form compact spheroids in vitro more rapidly than when the cell line was 
treated with shRNA targeting claudin 4, causing low levels of claudin 4 to be expressed. These results 
demonstrate a role for claudin 4 in spheroid formation and integrity, and lead us to speculate that 
claudin  4 may  play a  role in  mediating chemoresistance in spheroids by  increasing  tight junction 
barrier function or activation of prosurvival signaling. Furthermore, as the majority of cases of ovarian 
cancer examined exhibited elevated levels of claudin 4 protein expression, this supports the use of 
claudin 4 as a therapeutic target, and we postulate that blocking claudin 4 function may increase the 
efficacy  of  chemotherapy  delivered  intraperitoneally.  Indeed,  several  groups  have  reported  using 
claudin 4 as a target for delivery of toxins and fluorescent molecules to ovarian and breast cancer  
cells [70–72]. 
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